Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Sadia Anjum und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Hail, Hail, Saudia Arabia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Vincristine, Oncolytic Viruses, Oncolytic Virotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Prostate cancer is a prevalent carcinoma among males, and conventional treatment options are often limited. Cytotoxic chemotherapy, despite its drawbacks, remains a mainstay. We propose a targeted co‐delivery approach using nanoscale delivery units for Oncolytic measles virus (OMV) and vincristine (VC) to enhance treatment efficacy. The HA‐coated OMV + VC‐loaded TCs nanoformulation is designed for targeted oncolytic activity in prostate cancer. The CD44 expression analysis in prostate cancer cell lines indicates a significantly high expression in PC3 cells. The optimization of nanoformulations using Design of Expert (DOE) is performed, and the preparation and characterization of HA‐coated OMV + VC‐loaded TCs nanoformulations are detailed showing average particle size 397.2 ± 0.01 nm and polydispersity index 0.122 with zeta potential 19.7 + 0.01 mV. Results demonstrate successful encapsulation efficiency with 2.4 × 10 6 TCID50/Ml and sustained release of OMV and VC from the nanoformulation for up to 72 h. In vitro, assays reveal potent anticancer activity at 10 ± 0.71% cell viability in PC3 cells compared to 73 ± 0.66% in HPrEC and significant morphological changes at 90 µg/ml in dose and time‐dependent manner. The co‐formulation showed positive cell death 49.5 ± 0.02% at 50 µg PI/ml in PBS and 54.3% cell cycle arrest at the G2/M phase, 8.1% G0/G1 and 5.7% at S phase, with significant mitochondrial membrane potential (MMP) at 50 µg/ml, as assessed by flow cytometry (FACS). The surface‐integrating ligand approach enhances the targeted delivery of the oncolytic virus and chemotherapeutic drug, presenting a potential alternative for prostate cancer treatment and suggested that co‐administering VC and OMV in a nanoformulation could improve therapeutic outcomes while reducing chemotherapeutic drug doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Hail, Hail, Saudia Arabia.
- Department of Biosciences, Shifa Tameer e Millat University, Islamabad, Pakistan.
- Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
- Shifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
- Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, Jeddah, Saudia Arabia.
ORCID-Profile: Faiza Naseer
Zitieren
APA
Anjum, S., Naseer, F., Ahmad, T., Liaquat, A., Abduh, M. S., & Kousar, K. (2024). Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach. Journal of Medical Virology. https://doi.org/10.1002/jmv.29748
Vancouver
Anjum S, Naseer F, Ahmad T, Liaquat A, Abduh MS, Kousar K. Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach. Journal of Medical Virology. 2024. doi:10.1002/jmv.29748
BibTeX
@article{Anjum2024,
author = {Anjum, Sadia and Naseer, Faiza and Ahmad, Tahir and Liaquat, Afrose and Abduh, Maisa S and Kousar, Kousain},
title = {Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29748}
}
EUVIMED